QSAR model for CYP2D6 inhibition in the aryloxypropanolamine series.

被引：0
|
作者：
Gavai, AV [1 ]
Vaz, RJ [1 ]
Santone, K [1 ]
Chandrasena, G [1 ]
Nayeem, A [1 ]
机构：
[1] Bristol Myers Squibb Co, Pharmaceut Res Inst, Princeton, NJ 08543 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2003年 / 226卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
354-MEDI
引用
收藏
页码：U66 / U66
页数：1
相关论文
共 50 条
  • [21] INHIBITION OF CYP2D6 BY BUPROPION IN HEALTHY VOLUNTEERS.
    Duong, A.
    Gufford, B.
    Liu, S.
    Benson, E.
    Lu, J.
    Stoughton, C.
    Desta, Z.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S71 - S71
  • [22] DOSE DEPENDENT CYP2D6 INHIBITION BY BUPROPION AND LEVOMEPROMAZINE
    Haslemo, T.
    Arnestad, M.
    Molden, E.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 123 : 6 - 7
  • [23] In vitro inhibition of CYP2D6 activity by fenfluramine.
    Marcucci, K
    Gotschall, R
    Kearns, GL
    Leeder, JS
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (02) : 142 - 142
  • [24] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
    Gressier, F.
    Verstuyft, C.
    Hardy, P.
    Becquemont, L.
    Corruble, E.
    JOURNAL OF NEURAL TRANSMISSION, 2015, 122 (01) : 35 - 42
  • [25] CYP2D6 genotypes in a Japanese population:: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10
    Nishida, Y
    Fukuda, T
    Yamamoto, I
    Azuma, J
    PHARMACOGENETICS, 2000, 10 (06): : 567 - 570
  • [26] CYP2D6*36 gene arrangements within the CYP2D6 locus:: Association of CYP2D6*36 with poor metabolizer status
    Gaedigk, A
    Bradford, LD
    Alander, SW
    Leeder, JS
    DRUG METABOLISM AND DISPOSITION, 2006, 34 (04) : 563 - 569
  • [27] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
    F. Gressier
    C. Verstuyft
    P. Hardy
    L. Becquemont
    E. Corruble
    Journal of Neural Transmission, 2015, 122 : 35 - 42
  • [28] CYP2D6 multiallelism
    Daly, AK
    Steen, VM
    Fairbrother, KS
    Idle, JR
    CYTOCHROME P450, PT B, 1996, 272 : 199 - 210
  • [29] The Impact of the CYP2D6 "Enhancer" Single Nucleotide Polymorphism on CYP2D6 Activity
    Dinh, Jean C.
    Boone, Erin C.
    Staggs, Vincent S.
    Pearce, Robin E.
    Wang, Wendy Y.
    Gaedigk, Roger
    Leeder, James Steven
    Gaedigk, Andrea
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (03) : 646 - 654
  • [30] CYP2D6 polymorphism in a Gabonese population:: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype
    Panserat, S
    Sica, L
    Gérard, N
    Mathieu, H
    Jacqz-Aigrain, E
    Krishnamoorthy, R
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (01) : 121 - 124
12345